Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug648 | COVID-19 Therapeutic Vaccine - Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection Wiki | 0.63 |
| drug635 | COVID-19 FACILITY Wiki | 0.45 |
| drug2527 | Placebo Infusion Wiki | 0.45 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2777 | RO6953958 Wiki | 0.45 |
| drug3949 | lung ultrasound Wiki | 0.45 |
| drug2712 | Pulse Oximeter Wiki | 0.45 |
| drug985 | Daily Monitoring Wiki | 0.45 |
| drug639 | COVID-19 PCR Swab Wiki | 0.45 |
| drug919 | Cord Tissue Mesenchymal Stromal Cells Wiki | 0.45 |
| drug725 | Cannabidivarin Wiki | 0.45 |
| drug1183 | Emotional Support Plan Wiki | 0.45 |
| drug3705 | Wearable Medical Device (Empatica E4) Wiki | 0.45 |
| drug1714 | Interview by psychologists Wiki | 0.45 |
| drug1974 | Matched Placebo Wiki | 0.32 |
| drug644 | COVID-19 RT-PCR Wiki | 0.26 |
| drug2505 | Placebo Wiki | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001321 | Autistic Disorder NIH | 0.75 |
| D000067877 | Autism Spectrum Disorder NIH | 0.67 |
| D065886 | Neurodevelopmental Disorders NIH | 0.32 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000717 | Autism HPO | 0.75 |
| HP:0000729 | Autistic behavior HPO | 0.67 |
| HP:0002487 | Hyperkinetic movements HPO | 0.32 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0007018 | Attention deficit hyperactivity disorder HPO | 0.22 |
Navigate: Correlations HPO
There are 5 clinical trials
This trial aims to study the efficacy and safety of cannabidivarin (CBDV) in children with ASD.
Description: Change in ABC-I from Baseline to Endpoint
Measure: Aberrant Behavior Checklist-Irritability Subscale (ABC-I) Time: Change in ABC-I from Baseline to Week 12 (Change over 12 weeks)Description: Change in RBS-R from Baseline to Endpoint
Measure: Repetitive Behavior Scale-Revised (RBS-R) Time: Change in RBS-R from Baseline to Week 12 (Change over 12 weeks)Description: Change in ABC-SW from Baseline to Endpoint
Measure: Aberrant Behavior Checklist-Social Withdrawal Subscale (ABC-SW) Time: Change in ABC-SW from Baseline to Week 12 (Change over 12 weeks)Description: Change in PedsQL from Baseline to Endpoint
Measure: Pediatric Quality of Life Inventory (PedsQL) Family Impact Module Time: Change in PedsQL from Baseline to Week 12 (Change over 12 weeks)Description: Change in Vineland-3 from Baseline to Endpoint
Measure: Vineland Adaptive Behavior Scale-3 (Vineland 3) Time: Change in Vineland-3 from Baseline to Week 12 (Change over 12 weeks)Description: Change in CGI-I from Baseline to Endpoint
Measure: Clinical Global Impressions-Improvement (CGI-I) Time: Change in CGI-I from Baseline to Week 12 (Change over 12 weeks)Description: The MERS-R is designed to assess three domains of rigid behavior in children and adults with ASD: 1. Behavioral Rigidity (e.g., insistence on sameness, things must be done in his/her way, etc.) 2. Cognitive Rigidity (e.g., special interests, inflexible adherence to rules, etc.) 3. Protest (in response to deviation from rigidity; e.g., verbal objection, tantrum, physical aggression).
Measure: Montefiore Einstein Rigidity Scale-Revised (MERS-R) Time: Change in MERS-R from Baseline to Week 12 (Change over 12 weeks)The purpose of this Phase II study is to determine the efficacy of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) for improving social communication abilities in children with autism spectrum disorder (ASD).
Description: The primary outcome measure is the mean of the change on the Socialization and Communication Subscale Standard Scores on the Vineland Adaptive Behavior Scales (VABS-3). The primary endpoint is the change on this outcome measure from baseline to six months.
Measure: Change on the Socialization and Communication Subscale Standard Scores on the Vineland Behavior Scales Time: Baseline, 6 monthsDescription: Change in VABS-3 (Vineland Adaptive Behavior Scales) Socialization Standard Score
Measure: Change in VABS-3 Socialization Standard Score Time: Baseline, 6 monthsDescription: Change in VABS-3 (Vineland Adaptive Behavior Scales) Communication Standard Score
Measure: Change in VABS-3 Communication Standard Score Time: Baseline, 6 monthsDescription: Clinical Global Impression- Severity Scale
Measure: Change in CGI-Severity score Time: Baseline, 6 monthsDescription: Clinical Global Impression- Impression
Measure: CGI-Intervention score Time: Baseline, 6 monthsDescription: Pediatric Quality of Life Scale
Measure: Change in the Pediatric Quality of Life Scale Time: Baseline, 6 monthsDescription: Assess for infusion reactions
Measure: Incidence and severity of infusion reactions Time: Baseline, 6 monthsDescription: Assess for infections directly related to the study product infusions
Measure: Incidence and severity of product-related infections Time: Baseline, 6 monthsDescription: Assess for anti-HLA antibodies
Measure: Evidence of formation of anti-HLA antibodies Time: Baseline, 6 months, 12 monthsDescription: Assess for signs and symptoms of graft versus host disease
Measure: Incidence and severity of graft versus host disease Time: 6 months, 12 monthsDescription: Assess for study related and unexpected adverse events
Measure: Incidence and severity of unexpected adverse events related to the study product Time: Baseline, 6 months, 12 monthsIn response to the coronavirus disease 2019 (covid-19) outbreak, the home confinement of the population ordered by governments in many countries raise questions about its impact on individuals' physical and mental health in the short and longer term. In children, reduced physical activity, changes in lifestyle, disturbances in sleep patterns, lack of in-person contact with peers, poor or inadequate understanding of health risks may be risk factors of anxiety, stress, fatigue, sleep disorders (Brooks et al, 2020; Wang et al, 2020; Sprang et al, 2013). These problematic effects could be modulated by social factors (housing in urban or rural areas, availability of personal space at home, parenting stress, etc.) (Cluver et al, 2020; Liu et al, 2020).
Description: composition, home confinement, change in the environment, personal room at home, screens with internet access, parents' current professional status, teleworking, care, family concerns related to Covid-19, parenting stress, schooling, recurrent complaints.
Measure: Interview of the parents : contextual data Time: BaselineDescription: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)
Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general Time: BaselineDescription: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)
Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general Time: 1 monthDescription: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)
Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general Time: 3 monthsDescription: Data relating to disease and management of care. Experience of the referring caregiver.
Measure: Interview of the referring caregiver : data relating to disease and management of care Time: 3 monthsThe purpose of this study is to evaluate the feasibility, acceptability and effectiveness of a brief, telehealth intervention (the Emotional Support Plan), intended to support autistic adults to cope with their negative emotions during and/or after the COVID-19 pandemic. The first objective is to develop and refine a brief telehealth-delivered treatment, the Emotional Support Plan (ESP), to help promote adults to cope during periods of acute distress, such as those experienced during the COVID-19 pandemic. The second objective is to assess the feasibility and effectiveness of the ESP to support autistic adults to implement emotion regulation strategies during periods of acute distress. The last objective is to yield preliminary data to apply for extramural grants to validate these methods to monitor and support mental health of autistic adults during key transitions (e.g., starting college).
Description: The PHQ-9, assessed weekly, is a 9-item questionnaire of psychological function over the past week with all items on a "0" (not at all) to "3" (nearly every day) scale. Higher scores equal more distress.
Measure: Decreased distress on Patient Health Questionnaire (PHQ-9) Time: 8 week study periodDescription: EMA (Ecological Momentary Assessment) reports of decreased distress (in ESP + daily monitoring group only). Higher scores on the item equal higher levels of distress.
Measure: Decreased distress on EMA reports Time: 8 week study periodDescription: The GAD-7, assessed weekly, is a 7-item questionnaire of anxiety symptoms over the past week with all items on a "0" (not at all) to "3" (nearly every day) scale. Higher scores equal more anxiety.
Measure: Decreased anxiety symptoms on the Generalized Anxiety Disorder Questionnaire (GAD-7) Time: 8 week study periodDescription: The ASR is a measure of adaptive functioning and psychopathology (e.g., anxiety, depression symptoms). Most of the items are on a 3 point scale including: (0) Not true, (1) Somewhat or sometimes true, and (2) Very often or often true.
Measure: Adult Self Report (ASR) Time: 8 week study periodThis study will evaulate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single- and multiple-ascending doses (SAD and MAD) and food effect (FE) of RO6953958 following oral administration in healthy male participants.
Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports